How much funding has Sunesis raised?

Sunesis has raised $85.2M in total funding, most recently a Series B round.

Who are Sunesis's investors?

Sunesis's investors include Credit Suisse First Boston, Warburg Pincus.

What industry is Sunesis in?

Sunesis operates in Biotech, Healthcare.

Sunesis

Q: Where is Sunesis headquartered?

Sunesis is headquartered in South San Francisco, California, United States.

Advancing novel oncology therapeutics

South San Francisco, United States · Founded 1998 · $85.2M raised

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 11–50
Founded: 1998
Business Model: B2B

Website: sunesis.com
Total Funding: $85.2M
Last Round: $60.0M Series BJul 2000
Rounds: 2

About

Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing and commercializing novel oncology therapeutics. Founded in 1998 and incorporated in Delaware, the company applies its expertise in small-molecule drug discovery to advance treatments for hematologic and solid tumor malignancies. Its lead program, voreloxin, is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. Sunesis has built deep capabilities across all phases of oncology drug development, from preclinical research through Phase III clinical trials, partnering with leading academic and medical research institutions.

Summary

Sunesis is a Biotech company based in South San Francisco, United States, founded in 1998. It has raised $85.2M in total across 2 rounds, most recently a $60.0M Series B round in Jul 2000. Investors include Credit Suisse First Boston and Warburg Pincus.